Curis, Inc. (NASDAQ:CRIS) Short Interest Update

Curis, Inc. (NASDAQ:CRIS) was the target of a large increase in short interest in October. As of October 31st, there was short interest totalling 137,000 shares, an increase of 26.6% from the October 15th total of 108,200 shares. Based on an average daily volume of 55,800 shares, the short-interest ratio is presently 2.5 days. Currently, 1.8% of the shares of the stock are short sold.

Curis Stock Down 0.8 %

NASDAQ:CRIS traded down $0.03 on Friday, hitting $3.95. The stock had a trading volume of 96,519 shares, compared to its average volume of 40,146. The business’s fifty day moving average is $5.06 and its 200 day moving average is $7.21. The company has a market cap of $23.62 million, a PE ratio of -0.49 and a beta of 3.35. Curis has a 52 week low of $3.51 and a 52 week high of $17.49.

Institutional Trading of Curis

Several institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. raised its stake in shares of Curis by 4.8% in the first quarter. Vanguard Group Inc. now owns 218,573 shares of the biotechnology company’s stock worth $2,376,000 after purchasing an additional 10,097 shares during the last quarter. Focused Wealth Management Inc increased its holdings in Curis by 63.1% during the 3rd quarter. Focused Wealth Management Inc now owns 54,066 shares of the biotechnology company’s stock valued at $291,000 after purchasing an additional 20,908 shares during the period. CM Management LLC boosted its position in Curis by 380.0% during the 1st quarter. CM Management LLC now owns 120,000 shares of the biotechnology company’s stock valued at $1,304,000 after acquiring an additional 95,000 shares in the last quarter. Finally, Point72 Asset Management L.P. boosted its position in Curis by 795.5% during the 2nd quarter. Point72 Asset Management L.P. now owns 108,356 shares of the biotechnology company’s stock valued at $748,000 after acquiring an additional 96,256 shares in the last quarter. 29.97% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Curis in a research report on Friday.

About Curis

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.